Posted by AGORACOM-JC
at 11:17 AM on Tuesday, February 12th, 2019
Investment Highlights
Kenbridge property has a measured and indicated resource of 7.14 million tonnes at 0.62% nickel, 0.33% copper
17.5 (21.8 fully diluted) percent equity stake in Eloro Resources and 2 percent NSR in their La Victoria property
Kenbridge Ni Project (ON, Canada)
Advanced stage deposit remains open in three directions, is
equipped with a 623m deep shaft and has never been mined.
Preliminary Economic Assessment completed and updated returned robust project economics and operating costs including a NPV of C$253M and cash costs of US$3.47/lb of nickel net of copper credits.
Plans for Kenbridge include updating PEA,
advancing the project through to feasibility and exploring the open
mineralization at depth
FULL DISCLOSURE: Tartisan Nickel Corp. is an advertising client of AGORA Internet Relations Corp.
Posted by AGORACOM-JC
at 2:30 PM on Friday, February 8th, 2019
.
Announced the appointment of Mr. Aamer Siddiqui as Chief Financial Officer (CFO) of the Company.
Mr. Siddiqui is a Chartered Professional Accountant(CPA) and Chartered Accountant(CA), Chartered Professional Accountants of Canada.
TORONTO, ON / February 8, 2019 / Tartisan Nickel Corp. (CSE: TN, FSE: A2DPCM) (“Tartisan”, or the “Company”) is pleased to announce the appointment of Mr. Aamer Siddiqui as Chief Financial Officer (CFO) of the Company. Mr. Siddiqui is a Chartered Professional Accountant(CPA) and Chartered Accountant(CA), Chartered Professional Accountants of Canada.
Additionally, the Company reports that Tartisan Nickel has engaged
Marrelli Support Services Inc. to provide accounting support services to
the Company.
The Board of Directors of Tartisan Nickel would like to thank
outgoing CFO, Mr. Dan Fuoco, for his support and efforts during his
tenure and wish him well in his new endeavours.
About Tartisan Nickel Corp
The Company is a Canadian mineral exploration and development company
which owns the Kenbridge Nickel-Copper- Cobalt project in Ontario,
Canada. In addition, Tartisan owns a 100% stake in the Don Pancho
Zinc-Manganese Project and a 100% stake in the Ichuna Copper-Silver
Project, both located in Peru. Tartisan Nickel Corp also owns an equity
stake (6 million shares and 3 million full warrants at 40c per share),
in Eloro Resources Ltd. which is exploring the low-sulphidation
epithermal La Victoria Gold/Silver Project, located in Ancash, Peru.
The Company also owns 1,750,000 common shares of VaniCom Resources
Ltd. a private Australian exploration and development resource company.
Tartisan Nickel Corp. common shares are listed on the Canadian
Securities Exchange (CSE: TN, FSE: A2DPCM). Currently, there are
99,703,550 shares outstanding (108,803,550 fully diluted).
For further information, please contact Mr. D. Mark Appleby,
President & CEO and a Director of the Company, at 416-804-0280 ([email protected]). Additional information about Tartisan can be found at the Company’s website at www.tartisannickel.com or on SEDAR at www.sedar.com.
Jim Steel MBA P.Geo. is the Qualified Person under NI 43-101 and has
read and approved the technical content of this News Release.
This news release may contain forward-looking statements
including but not limited to comments regarding the timing and content
of upcoming work programs, geological interpretations, receipt of
property titles, potential mineral recovery processes, etc.
Forward-looking statements address future events and conditions and
therefore, involve inherent risks and uncertainties. Actual results may
differ materially from those currently anticipated in such statements.
The Canadian Securities Exchange (operated by CNSX Markets Inc.)
has neither approved nor disapproved of the contents of this press
release.
Posted by AGORACOM-JC
at 2:29 PM on Thursday, February 7th, 2019
Announced change in their Drug Development Plan (DDP) priorities.
This will allow Tetra to rapidly leverage the PANAG pipeline and expertise and align its research programs on indications with unmet medical needs or a higher return on investment (ROI).Â
Last Week’s Agreement to Acquire PANAG Establishes Exhaustive Dermatology and Ophthalmic Product Portfolios
ORLEANS, Ontario, Feb. 07, 2019 – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, today announced a change in their Drug Development Plan (DDP) priorities. This will allow Tetra to rapidly leverage the PANAG pipeline and expertise and align its research programs on indications with unmet medical needs or a higher return on investment (ROI). Through an expanded and focused pipeline, the Corporation intends to maintain its position as a leader in cannabis and cannabinoid drug development with a clear objective to generate value for shareholders.  In addition to its DDP in oncology and neuropathic pain programs, Tetra will pursue the development of prescription products in ophthalmic, dermatology as well as other pain segments.
Tetra Bio-Pharma Drug Development Plans address key therapeutic
sectors which address the medical needs of millions of patients and
represent substantial potential revenue. Priorities are summarized
below:
“Immediately following the PANAG closing we held an Executive Team
Meeting to prioritize our solid and robust prescription product pipeline
and ensure we maintain our lead in the cannabis prescription drug
market,†stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma.
“The products in this pipeline address high potential unmet medical
needs, such as uveitis, corneal neuropathic pain, interstitial cystitis,
fibromyalgia and glioblastoma. Some of these products will come from
PANAG’s pipeline and medical and scientific expertise. These innovative
products target disease indications with global unmet medical needs and
where we are confident that cannabinoid-derived products can play an
important role in alleviating pain, discomfort and associated symptoms.â€
Dr. Chamberland further stated, “The news on Tuesday is a reality in
the world of drug development. The safety and wellness of patients is
always Tetra’s number one priority. We also kept in mind the
importance and responsibility of taking a first cannabinoid drug to the
market. Our responsibility was to ensure timely and accurate disclosure
of the events subsequent to the results of the mycotoxin analyses of
the clinical trial lots which arrived on January 22nd and February 1st.
Tetra, and its Executive Team is engaged in a rapid transformational
change with the PANAG acquisition which will enable Tetra to mitigate
the risk that comes with developing a pharmaceutical drug while creating
value for shareholders. As some of our peers have demonstrated, a
single approved drug, even for a rare disease indication, can play a
significant role in our valuation.â€
Dr. Chamberland goes on to say, “It was my responsibility to rapidly
adjust our research priorities while we address the impurity issue and
risk to cancer patients. Although our DDP in Advanced Cancer Pain is
temporarily suspended, we had been assessing our PPP001 research data
and planned to accelerate DDP programs that address more diseases or
health conditions with a larger ROI. Down the road this transformation
will provide us with a more sustainable and robust product pipeline. The
Leadership Team is engaged to stay focused on these research
priorities, and rest assured that we will deliver value to our
shareholders.â€
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical
leader in cannabinoid-based drug discovery and development with a Health
Canada approved, and FDA reviewed, clinical program aimed at bringing
novel prescription drugs and treatments to patients and their healthcare
providers. The Company has several subsidiaries engaged in the
development of an advanced and growing pipeline of Bio Pharmaceuticals,
Natural Health and Veterinary Products containing cannabis and other
medicinal plant-based elements. With patients at the core of what we do,
Tetra Bio-Pharma is focused on providing rigorous scientific validation
and safety data required for inclusion into the existing bio pharma
industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements Some statements in
this release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will or
may occur in the future (including, without limitation, statements
regarding potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable by use
of the words “may”, “will”, “should”, “continue”, “expect”,
“anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or
the negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company’s ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results or
events to differ materially from current expectations include, among
other things, without limitation, the inability of the Company to obtain
sufficient financing to execute the Company’s business plan;
competition; regulation and anticipated and unanticipated costs and
delays, the success of the Company’s research and development
strategies, including the products mentioned in this release, the
applicability of the discoveries made therein, the successful and timely
completion and uncertainties related to the regulatory process
including the applications for Orphan Drug Designation, the timing of
clinical trials, the timing and outcomes of regulatory or intellectual
property decisions and other risks disclosed in the Company’s public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify important
factors that could cause actual results or events to differ materially
from those described in forward-looking statements, there may be other
factors that cause results or events not to be as anticipated, estimated
or intended. Readers should not place undue reliance on forward-looking
statements. While no definitive documentation has yet been signed by
the parties and there is no certainty that such documentation will be
signed. The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or otherwise
unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc. Robert (Bob) Bechard Executive Vice President, Corporate Development and Licensing 514-817-2514 [email protected]
Media Contact energi PR Carol Levine [email protected] 514-288-8500 ext. 226
Tags: pharma, tsx, tsx-v Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TPB.ca Pursues Its Research Priorities Accelerating Other Drug Development Plans
Posted by AGORACOM-JC
at 3:54 PM on Wednesday, February 6th, 2019
The heartbeat of cardiovascular medicine and telemedicine
Specializing in the software engineering of computer based
electrocardiogram (heart monitoring) management and reporting software
Software permits physician interpretations of ECGs and supports private and public payer fee-for-service billings
ECGs are electrical recordings of the heart and performing an ECG is one of the most common diagnostic tests performed
Successfully launched technologies that enable the use of new
medical devices and communication portals utilizing internet and
cellular based technologies for the recording, transmission and viewing
of ECGs
Recent Highlights
CardioComm Solutions’ HeartCheck(TM) Device Enters Final FDA Review Phase Read More
Completed a request for additional information from the US Food and
Drug Administration (“FDA”) for the Company’s premarket notification
510(k), Class II medical device clearance application for the
HeartCheck™ CardiBeat and GEMS™ Mobile Application.
Company had submitted a letter of revocation of their supplementary
information submission on December 26, 2018 in compliance with the FDA’s
directive
CardioComm Solutions’ HeartCheck(TM) CardiBeat and Smart Phone App Enter Final Stage of FDA 510(k) Review Read More
Market Release of HeartCheck(TM) CardiBeat and GEMS(TM) Mobile Application Set For Early 2019
Completed its response to the USA Food and Drug Administration for
additional information following the Company’s filing of its premarket
notification 510(k)
Class II medical device clearance application for the HeartCheck™ CardiBeat and GEMS™ Mobile Application
HeartCheck™ CardiBeat is the second of several planned Bluetooth-enabled ECG recording devices to be marketed by the Company
Launched 12-Lead ECG Smart Wearable Garment Monitoring Solution Read More
Announced joint partnership sales plans for the commercial launch of
its newest software release designed to support an innovative and easy
to use wireless, 12 lead ECG, vital signs, arrhythmia and ischemia
monitoring wearable smart garment manufactured by Israel-based
HealthWatch Technologies Ltd.
Company to Receive Royalty Payments from Biotricity Read More
Confirmed progress on a royalty licencing agreement with Biotricty Inc.
Royalty payment phase became active following confirmation that all
necessary clearance and software development pre-conditions have been
achieved
Royalty fees are due from the use of the ECG software Cardiocomm
developed, or any derivative products, on a per patient monitored basis
First Company to Receive Approval for ECG Product Sales Direct to Consumers Read More
CardioComm was the first company to be approved to sell an ECG
product directly to consumers in North America as evidenced by OTC Class
II medical device clearances by both the United States Food and Drug
Adminstration and Health Canada in 2012
HeartCheck ECG PEN is currently available for OTC sales on the shelves of Canadian pharmacy chain Shoppers Drug Mart.
Completed
HeartCheck(TM) Clinical Validation for Long-Term, Self-Managed, Remote
Monitoring of Atrial Fibrillation Patients Post-Ablation Read More
Moved into routine clinical use following completion of a long-term, remote arrhythmia monitoring pilot in high risk patients.
PACE cardiologists have been prescribing use of the HeartCheck™ ECG
PEN and ECG Handheld Monitor to their patients to provide up to one year
of enhanced remote patient monitoring for arrhythmias in addition to
use of conventional but term-limited Holter and event monitoring.
Products
HeartCheck™ Pen
The HeartCheck™ PEN handheld ECG device is the only device of its kind cleared by the FDA for consumer use.
✓ Monitor For Arrhythmias Anywhere ✓ Web Access to a Qualified Physician ✓ No Prescription Required
The pocket-sized PEN allows you to take heart readings from anywhere, the moment symptoms appear.
The HeartCheck™ ECG Device
The FDA-cleared HeartCheck™ ECG device is portable, easy to use and can store up to 200 thirty second ECG readings.
Whether at home, the gym or at the office, the HeartCheck™ ECG Device
with SMART Monitoring can help detect and monitor arrhythmias from
wherever you are.
Features & Benefits ✓ SMART Monitoring ECG Interpretations ✓ Cleared by the Food and Drug Administration (FDA) ✓ Easy to use ✓ Accurate heart readings in only 30 seconds ✓ Store up to 200 ECGs
Company Accolades
FULL DISCLOSURE: CardioComm Solutions Inc. is an advertising client of AGORA Internet Relations Corp.
Posted by AGORACOM-JC
at 11:09 AM on Tuesday, February 5th, 2019
Investment Highlights
Kenbridge property has a measured and indicated resource of 7.14 million tonnes at 0.62% nickel, 0.33% copper
17.5 (21.8 fully diluted) percent equity stake in Eloro Resources and 2 percent NSR in their La Victoria property
Kenbridge Ni Project (ON, Canada)
Advanced stage deposit remains open in three directions, is
equipped with a 623m deep shaft and has never been mined.
Preliminary Economic Assessment completed and updated returned robust project economics and operating costs including a NPV of C$253M and cash costs of US$3.47/lb of nickel net of copper credits.
Plans for Kenbridge include updating PEA,
advancing the project through to feasibility and exploring the open
mineralization at depth
FULL DISCLOSURE: Tartisan Nickel Corp. is an advertising client of AGORA Internet Relations Corp.
Tags: nickel, tsx-v Posted in AGORACOM Client Feature, All Recent Posts, Tartisan Nickel | Comments Off on CLIENT FEATURE: Tartisan Nickel $TN.ca Kenbridge Property Hosts M&I Resource of 7.14 Million Tonnes at 0.62% Nickel, 0.33% Copper $ROX.ca $FF.ca $EDG.ca $AGL.ca $ANZ.ca
Posted by AGORACOM-JC
at 10:21 AM on Tuesday, February 5th, 2019
SPONSOR: ThreeD Capital Inc. (IDK:CSE) Led by
legendary financier, Sheldon Inwentash, ThreeD is a Canadian-based
venture capital firm that only invests in best of breed small-cap
companies which are both defensible and mass scalable. More than just
lip service, Inwentash has financed many of Canada’s biggest small-cap
exits. Click Here For More Information.
Facebook’s latest move proves it’s betting big on blockchain tech
The next major objective on Facebook’s roadmap seems to be the blockchain.
Over the years, Mark Zuckerberg has made a number of smart moves that
only helped him expand the reach of Facebook and improve the outlook of
the business going forward. Purchases including WhatsApp, Instagram,
and Oculus allowed Facebook to grow its customer base and monetize even
more user data via ads, compete better against other image and
video-based social networks, and develop new hardware and software
experiences targeting VR users. The next major objective on Facebook’s
roadmap seems to be the blockchain. The company has already confirmed its working on blockchain technology, and reports said Facebook will release its own cryptocurrency in the future,
in the form of a stable coin that will be pegged against the dollar.
It’s unclear when that will happen, but Facebook just made a significant
move that further proves it’s serious about the blockchain.
No matter where the Bitcoin price will go next,
blockchain technology is here to stay, as it offers a number of
advantages for payments and other applications. Facebook’s team is led
by former PayPal president David Marcus, who’s been working on Messenger
before that. And Facebook’s blockchain team has just gotten
significantly bigger, as the company acqui-hired the team behind
Chainspace.
The startup was founded by researchers from University College London, according to Cheddar, and was working on “smart contracts†technology that would leverage blockchain tech for payments and other services.
Four of the five researchers behind Chainspace’s white paper are
joining the Facebook blockchain group, people familiar with the matter
said. Two of them, including Alberto Sonnino and George Danezis, already
list Facebook as their employer. Chainspace’s website was also updated
to note that the team is “moving on to something new.â€
Facebook confirmed that it hired employees from Chainspace without disclosing any other details about the move.
Following Cheddar, Mashable also reported
that Facebook acquired four key people behind the Chainspace tech. That
tech, however, isn’t the scope of Facebook’s purchase, as the company
only acquired the researchers behind it.
“Chainspace code and documentation will still be open source, and all
previously published academic work remains available,†the note on the startup’s website says.
Posted by AGORACOM-JC
at 4:37 PM on Monday, February 4th, 2019
SPONSOR: Esports Entertainment
$GMBL Esports audience is 350M, growing to 590M, Esports wagering is
projected at $23 BILLION by 2020. The company has launched VIE.gg
esports betting platform and has accelerated affiliate marketing
agreements with 190 Esports teams. Click here for more information
GMBL: OTCQB
How does League’s Worlds viewership compare to the Super Bowl?
The amount of people that watch the big events in esports has a direct correlation to how many people care about any particular esports league.
The League of Legends World Championship, for instance, can rack up tens of millions of viewers for a single best-of-five series, depending on the location and teams involved.
One of the most important metrics to look at when evaluating the
success of the esports industry at large is viewership statistics. Why?
Well, it’s obvious. The amount of people that watch the big events in
esports has a direct correlation to how many people care about any
particular esports league. The League of Legends World
Championship, for instance, can rack up tens of millions of viewers for a
single best-of-five series, depending on the location and teams
involved.
One of our favorite comparisons to make is weighing the viewers of League
esports to viewers of the NFL’s Super Bowl. The NFL is one of the most
popular traditional sports in North America, and with how often the “Are
esports considered sports?†debate is thrown around, it’s interesting
to see how the two compete side-by-side.
So let’s see the numbers. How close is the competitive League
scene to catching the Super Bowl in terms of viewership? Well, the
answer is a little shocking, because it’s a lot closer than you may have
thought. The Super Bowl typically nets around 110 million unique
viewers, according to
stats site Sports Media Watch. At least, it has every year since 2011,
with one exception in 2018 when it only reached 103 million. In 2011, it
hit 106 million, but the total didn’t breach 100 million at all before
that. Every year prior to 2011, the norm was around 90 million.
The League World Championship, or Worlds, clocked in at 99.6 million viewers in 2018 for the final series, according to stats provided directly by Riot Games, League’s developer. That means the difference between American football’s biggest event and League’s biggest event in 2018 was a mere 3.4 million people—103 million for the Super Bowl and 99.6 million for League’s Worlds.
Unfortunately, Riot doesn’t provide the
same statistics every year and for every event, which makes comparing
Worlds’ progression with the Super Bowl year by year more difficult.
League’s past couple of Worlds have had comparable numbers, though, with 2017’s hitting 80 million live viewers in the semifinals. Riot also shared
viewing statistics from that year’s Mid-Season Invitational, but
unfortunately it didn’t provide the amount of viewers for any one series
of the tournament. For example, Riot shared the total number of viewers
over the course of the entire MSI 2017 tournament, 364 million, but it
didn’t share the total number of viewers for either the finals or
semifinals series alone like it did for Worlds in 2017 and 2018
respectively. It’s currently unclear why Riot reveals stats in such a
sporadic way.
Unfortunately, Sports Media Watch hasn’t released data on 2019’s
Super Bowl, but when it does, we will update this story comparing 2018’s
Worlds to 2019’s Super Bowl.
Posted by AGORACOM-JC
at 2:55 PM on Monday, February 4th, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Click Here For More Information
NBUD: CSE
—————
New Cannabis Products Which Could Disrupt the Industry in 2019
If there is one large-scale category of cannabis product which is likely to emerge in 2019, it is edibles.
When Canada moved to legalize recreational marijuana usage among adults, it did not include regulations for edibles and other products which might be confused for non-cannabis alternatives
The cannabis industry enjoyed tremendous investor enthusiasm in 2018,
fueled in large part by major developments which seemed to open up the
space for new opportunities. Canadian legalization of recreational
marijuana use, the continued adoption of legal medical or recreational
cannabis in more states across the U.S., and high-profile achievements
from some of the industry’s emerging top contenders all fueled interest.
In spite of the fact that cannabis stocks overall failed to perform up
to expectations last year, 2019 has already revealed continued anticipation regarding this growing industry.
If cannabis stocks are to thrive going forward,
it’s likely that many companies will have some growing up to do.
Overextended balance sheets will need to be strengthened, highly
speculative mergers and acquisitions must be kept in check, and
quarterly figures will have to confirm that there is good reason for the
hype surrounding these companies.
One way that up-and-coming marijuana businesses can bolster their fortunes in 2019 is through the release of new cannabis-based products.
While it’s true that there has already been a flood of new marijuana
products to the market, it’s likely that only a few will emerge as
winners capable of driving sales and firming up particular companies’
dominant status in this fledgling market. Below, we’ll take a look at
some new cannabis products which may be able to change the game in this
way.
Edibles
If there is one large-scale category of cannabis product which is
likely to emerge in 2019, it is edibles. When Canada moved to legalize
recreational marijuana usage among adults, it did not include
regulations for edibles and other products which might be confused for
non-cannabis alternatives. The Canadian government allowed itself a
one-year window from the initial legalization date of October 17, 2018
to sort out regulations for edibles products. In the meantime, Canadian
marijuana companies have gotten a head start on developing new cannabis
edibles for retail sale, even as retailers are giving away product that
they are not yet allowed to sell. A recent survey indicated that about a quarter of Canadian cannabis customers had received a free edible in the last month.
When Canadian edibles become legal for retail sale on or before
October 17, 2019, expect a rush to get these products into retail shops.
Edibles alone could become a billion-dollar industry in the years to
come.
Cannabis Beverages
One of the biggest cannabis headlines of 2018 reported on news that Constellation Brands (STZ), the beverage company behind Corona and Modelo brand beers, had partnered with Canopy Growth Corp. (CGC),
the largest cannabis producer in Canada. The alignment of a major
cannabis company with a top producer of alcoholic beverages has many
analysts and investors speculating that there could be joint product
launches in the near future. Indeed, other pairs of companies have also
matched up in recent months as well: Molson Coors announced a partnership with Canadian producer HEXO also.
It’s unlikely that any existing products from companies like
Constellation and Molson will change because of these partnerships.
However, expect a THC-infused beverage market to crop up as a
subcategory of the larger edibles space. These products could include
THC- or cannabidiol (CBD)-infused juices, waters and seltzers or
coffees. CBD products may be marketed as “health” drinks aimed at
reducing anxiety and inflammation without generating a “high” feeling in
the same way that THC does.
Cannabidiol Products
Before 2018 was finished, CBD had already begun to make its way into
all manner of products for sale. Although cannabis includes dozens of
chemical components, CBD has emerged early on as a popular one for
extraction and subsequent inclusion in drinks, vaping products, bath
bombs and more. CBD has been marketed as a product with wide-ranging
health benefits which can help to cure everything from pain to insomnia.
While it’s difficult to say exactly how accurate this claim is, it has
nonetheless been sufficient to generate widespread interest in CBD, even
among consumers not interested in the traditional “high” associated
with cannabis. Expect a continued proliferation of CBD-based products in
the months to come. Beauty and skin care products are among the most
popular of these new offerings.
Cannabidiol has also made its way into drug treatments developed in
the medical marijuana space. Indeed, the first FDA-approved
cannabis-based drug makes use of a pharmaceutical CBD oil. Companies
like GW Pharmaceuticals (GWPH) and Cara Therapeutics (CARA)
are rushing to develop and test new CBD-based drug treatments. While
this process takes a much longer time than the development of retail
CBD-based products, it has the potential for tremendous industry-wide
staying power, not to mention the benefit of providing more evidence of
the efficacy of medical marijuana on a broader level.
Posted by AGORACOM-JC
at 8:14 AM on Monday, February 4th, 2019
Announces that the Company and its recently acquired subsidiary Solutions Isoneo Inc. and CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE, have signed a cooperation agreement for the Emergency Medical Services (“EMSâ€) markets
Will enable them to provide real-time monitoring of patients while in transit on the ground or in the air.
TORONTO, Feb. 04, 2019 – Star Navigation Systems Group Ltd. (CSE: SNA) (OTCQB: SNAVF) (CSE:SNA.CN) (“Star” or the “Company”) announces that the Company and its recently acquired subsidiary Solutions Isoneo Inc. (to be renamed STAR-ISONEO Inc. -see press release January 16, 2019) and CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE, (https://www.chusj.org)  have signed a cooperation agreement for the Emergency Medical Services (“EMSâ€) markets which will enable them to provide real-time monitoring of patients while in transit on the ground or in the air.
CHUSJ is one of the top 10 mother-child hospitals in the World, with
over 3500 births a year. It has over 1500 nurses, over 500 Doctors and
over 200 researchers on staff. As a university hospital centre, the
CHUSJ brings together, in one location, patient care, research,
teaching, technological assessment, rehabilitation and health promotion.
The parties will work on the application of the STAR-A.D.S. ® System
to the EMS field, utilizing STAR equipment known as In-Flight System
Aided Medical Monitoring (“STAR-ISAMM™â€) for air ambulance applications
and Land System Aided Medical Monitoring, (“STAR-LSAMM™â€) addressing
Ground ambulances.
STAR and STAR-ISONEO are directly working on the hardware and
software component of the systems, while CHUSJ, as a subject-matter
expert, is working on the medical operations and environment. As an
illustration, the CHUSJ is tasked with the definition and the
realization of the medical users visual interface of the solution.
The parties have already successfully presented the solution in
Montreal in late 2018, and STAR will be responsible for the marketing
and sales of this unique EMS solution.
About Star Navigation: Star Navigation Systems Group Ltd. owns the exclusive worldwide license to its proprietary, patented In-flight Safety Monitoring System, STAR-ISMS®, the heart of the STAR-A.D.S. ® System. Its real-time capability of tracking performance trends and predicting incident-occurrence enhances aviation safety and improves fleet management while reducing costs for the operator.
Star’s MMI Division designs and manufactures high performance,
mission critical, flight deck flat panel displays for defence and
commercial aviation industries worldwide.
Certain statements contained in this News Release constitute
forward-looking statements. When used in this document, the words “may,
“would”, “could”, “will” and similar expressions, as they relate to Star
or its management are intended to identify forward-looking statements.
Such statements reflect Star’s current views with respect to future
events and are subject to certain risks, uncertainties and assumptions.
Many factors could cause Star’s actual performance or achievements to
vary from those described herein. Should one or more of these factors or
uncertainties materialize, or should assumptions underlying
forward-looking statements prove incorrect, actual results may vary
materially from those described herein as intended, planned,
anticipated, believed, estimated or expected. Star does not assume any
obligation to update these forward-looking statements, except as
required by law.
Neither Canadian Securities Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the Canadian
Securities Exchange) accepts responsibility for the adequacy or accuracy
of the content of this release.
Posted by AGORACOM-JC
at 8:07 AM on Friday, February 1st, 2019
Announce the launch of their Learner Assistant which supports learners as they explore and access educators’ content from around the world through a Google Chrome browser extension
betterU has been working to ensure that the learner’s user experience is properly guided, managed and supported for a life-time of learning.
OTTAWA, Ontario, Feb. 01, 2019 — betterU Education Corp. (the “Company” or “betterU”) is pleased to announce the launch of their Learner Assistant which supports learners as they explore and access educators’ content from around the world through a Google Chrome browser extension.
One of the challenges faced while building a solution that provides
access to global educators is the ability for the Company to support a
learner while they are working in different learning environments. With
thousands of global Ed-Tech providers, different learning technologies
and varying student registration processes, a learner may experience
multiple challenges as they move from educator to educator. betterU has
been working to ensure that the learner’s user experience is properly
guided, managed and supported for a life-time of learning. The Learner Assistant is just one of the many solutions betterU has been putting in place to support their vision providing access to Education for All.
With the new Learner Assistant, learners can access learning
content through betterU’s platform and seamlessly transition into a new
learning environment while still being able to:
Search and compare learning content provided through betterU
View purchase history, wish list, recommendations and job opportunities
Receive recommendations of courses based on their profile
Access and view saved jobs and additional employment recommendations
Rate courses immediately after completion
Communicate with betterU at any time through our live chat, email support and call centre
Receive notifications about new courses and exclusive offers
Manage global learning paths, access
study abroad opportunities, apply for internships, view corporate
opportunities, manage skills advancements, complete assessments and much
more (coming 2019)
The betterU Learner Assistant will be made available to each
learner who registers with betterU. The application (app) can also be
downloaded for free from Google’s Chrome Store
In parallel to acquiring content partnerships and building support technologies such as the Learner Assistant,
betterU has been working to solve for the skill shortage affecting 100s
of millions of people globally. There are thousands of jobs across
industries such as health care, hospitality, aerospace, telecom and
more. Each job carries multiple knowledge and skill requirements that
many are now realizing they do not meet. betterU’s
education-to-employment ecosystem brings together a collaboration of
global educators whose offerings support the acquisition of skills
required for employment. However, access to a massive global library of
content is only part of the solution. It is important to also integrate
the understanding of the education and skill requirements for every job
profile and connect those requirements and opportunities to learners in
need.
India’s National Occupational Standards (NOS) specify the standard of
performance an individual must achieve when carrying out a function in
the workplace, together with the knowledge and understanding they need
to meet a standard consistently.1 The NOSs were produced by each
industry Sector Skill Council (SSC) and are based on global standards.
Leveraging the efforts of the country, betterU extracted the profiles
which define the educational, professional, technical and generic skill
requirements, as well as other key details and set to work on a skilling
solution.
With use of technology, betterU has mapped all job profiles within
the major industries and created a massive database of course
recommendations which are connected to learning content offered by our
global partners. Through a simple and interactive learner assessment,
betterU can now analyse and recommend learning solutions to an
individual by understanding their job interests and assessing their
education and skill levels. After the assessment is complete, betterU
can guide a learner towards appropriate learning paths to help learners
achieve their goals for employment. The Company has been focused on the
skill shortage problem for years and is pleased to announce it has
completed the first prototype of their Upskill Tool. betterU expects to complete their Upskill Tool over the next quarter and be able to support India’s national skills shortages.
betterU, a global education to employment platform, aims to provide
access to quality education from around the world to foster growth and
opportunity to those who want to better their lives. The company plans
to bridge the prevailing gap in the education and job industry and
enhance the lives of its prospective learners by developing an
integrated education-to-employment ecosystem. betterU’s offerings can be
categorized into several broad functions: to compliment school programs
with flexible KG-12 programs preparing children for next stage of
education, to provide access to global educational opportunities from
leading educators, to foster an exceptional educational environment by
providing befitting skills that lead to a better career, to bridge the
gap between one’s existing education and prospective job requirement by
training them and lastly, to connect the end user to various job
opportunities.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
This press release may contain forward-looking statements and
information, which may involve risks and uncertainties. The results or
events predicted in these statements may differ materially from actual
results or events. Factors that might cause a difference include, but
are not limited to, competitive developments, risks associated with
betterU’s growth, the state of the financial markets, regulatory risks
and other factors. There can be no assurance or guarantees that any
statements of forward-looking information contained in this release will
prove to be accurate. Actual results and future events could differ
materially from those anticipated in such statements. These and all
subsequent written and oral statements containing forward-looking
information are based on the estimates and opinions of management on the
dates they are made and expressly qualified in their entirety by this
notice. Unless otherwise required by applicable securities laws, betterU
disclaims any intention or obligation to update or revise any
forward-looking statements, whether because of new information, future
events or otherwise. Readers should not place undue reliance on any
statements of forward-looking information that speak only as of the date
of this release. Further information on betterU’s public filings,
including their most recent audited consolidated financial statements,
are available at www.sedar.com.
